1. Home
  2. WRAP vs BDTX Comparison

WRAP vs BDTX Comparison

Compare WRAP & BDTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Wrap Technologies Inc.

WRAP

Wrap Technologies Inc.

SELL

Current Price

$1.13

Market Cap

106.5M

Sector

Industrials

ML Signal

SELL

Logo Black Diamond Therapeutics Inc.

BDTX

Black Diamond Therapeutics Inc.

SELL

Current Price

$1.43

Market Cap

104.0M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
WRAP
BDTX
Founded
2016
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Ordnance And Accessories
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
106.5M
104.0M
IPO Year
2017
2020

Fundamental Metrics

Financial Performance
Metric
WRAP
BDTX
Price
$1.13
$1.43
Analyst Decision
Buy
Analyst Count
0
8
Target Price
N/A
★ $11.00
AVG Volume (30 Days)
507.4K
★ 868.2K
Earning Date
11-16-2026
11-10-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 130.71
EPS
★ N/A
N/A
Revenue
★ $4,672,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
★ 3.66
N/A
52 Week Low
$0.98
$1.40
52 Week High
$6.00
$4.06

Technical Indicators

Market Signals
Indicator
WRAP
BDTX
Relative Strength Index (RSI) 38.37 36.89
Support Level N/A N/A
Resistance Level $1.71 $1.94
Average True Range (ATR) 0.14 0.15
MACD 0.01 -0.03
Stochastic Oscillator 8.50 3.57

Price Performance

Historical Comparison
WRAP
BDTX

About WRAP Wrap Technologies Inc.

Wrap Technologies Inc is a public safety technology and services company that delivers safe and effective policing solutions to law enforcement and security personnel. The firm develops policing solutions to law enforcement and security personnel. Its BolaWRAP 150 Remote Restraint device is a patented, hand-held tool that discharges a Kevlar cord to restrain noncompliant individuals from a range of 10-25 feet. The group operates in the Americas, Europe, the Middle East, Africa and the Asia Pacific.

About BDTX Black Diamond Therapeutics Inc.

Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The foundation of companies has been built upon a deep understanding of cancer genetics, onco-protein structure and function, and medicinal chemistry. Its clinical-stage program, silevertinib (formerly BDTX-1535), a brain-penetrant, fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor, is currently being studied in a Phase 2 clinical trial in patients with epidermal growth factor receptor mutant (EGFRm) non-small cell lung cancer (NSCLC). The Company manages its operations as a single operating segment and single reportable segment.

Share on Social Networks: